Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations

Bortezomib (BTZ) is the first proteasome inhibitor approved by the Food and Drug Administration. It can bind to the amino acid residues of the 26S proteasome, thereby causing the death of tumor cells. BTZ plays an irreplaceable role in the treatment of mantle cell lymphoma and multiple myeloma. More...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jianhao, Zhao, Ruogang, Jiang, Xiaowen, Li, Zhaohuan, Zhang, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773474/
https://www.ncbi.nlm.nih.gov/pubmed/35053199
http://dx.doi.org/10.3390/biom12010051

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773474/
https://www.ncbi.nlm.nih.gov/pubmed/35053199
http://dx.doi.org/10.3390/biom12010051

Ejemplares similares